MX362132B - Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado. - Google Patents

Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.

Info

Publication number
MX362132B
MX362132B MX2013013096A MX2013013096A MX362132B MX 362132 B MX362132 B MX 362132B MX 2013013096 A MX2013013096 A MX 2013013096A MX 2013013096 A MX2013013096 A MX 2013013096A MX 362132 B MX362132 B MX 362132B
Authority
MX
Mexico
Prior art keywords
therapy
therapeutic
methods
disease activity
therapy management
Prior art date
Application number
MX2013013096A
Other languages
English (en)
Other versions
MX2013013096A (es
Inventor
Singh Sharat
Ohrmund Linda
Hauenstein Scott
Hoe Nicholas
Lockton Steve
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013013096A publication Critical patent/MX2013013096A/es
Publication of MX362132B publication Critical patent/MX362132B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para manejo terapéutico personalizado de una enfermedad para de esta manera optimizar la terapia y/o monitorear la eficacia terapéutica. En particular, la presente invención comprende medir una disposición de uno o una pluralidad de biomarcadores en una pluralidad de puntos de tiempo durante el curso de terapia con un agente terapéutico para determinar un índice de sanación de mucosas para seleccionar terapia, optimizar terapia, reducir toxicidad y/o monitorear la eficacia de tratamiento terapéutico. En ciertos casos, el agente terapéutico es un inhibidor de TNFa para el tratamiento de de una enfermedad o trastorno mediado por TNFa.
MX2013013096A 2011-05-10 2012-05-10 Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado. MX362132B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161484607P 2011-05-10 2011-05-10
US201161505026P 2011-07-06 2011-07-06
US201161553909P 2011-10-31 2011-10-31
US201161566509P 2011-12-02 2011-12-02
US201261636575P 2012-04-20 2012-04-20
PCT/US2012/037375 WO2012154987A1 (en) 2011-05-10 2012-05-10 Methods of disease activity profiling for personalized therapy management

Publications (2)

Publication Number Publication Date
MX2013013096A MX2013013096A (es) 2014-07-14
MX362132B true MX362132B (es) 2019-01-07

Family

ID=46147068

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013013096A MX362132B (es) 2011-05-10 2012-05-10 Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
MX2018008324A MX2018008324A (es) 2011-05-10 2013-11-08 Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018008324A MX2018008324A (es) 2011-05-10 2013-11-08 Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.

Country Status (14)

Country Link
US (3) US10086072B2 (es)
EP (1) EP2707504A1 (es)
JP (3) JP2014517279A (es)
KR (1) KR20140032424A (es)
CN (2) CN103649336A (es)
AU (1) AU2012253422B2 (es)
BR (1) BR112013028808A2 (es)
CA (1) CA2839792A1 (es)
IL (1) IL229120B (es)
MX (2) MX362132B (es)
RU (1) RU2013154566A (es)
SG (1) SG194710A1 (es)
WO (1) WO2012154987A1 (es)
ZA (1) ZA201309258B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
MX362132B (es) 2011-05-10 2019-01-07 Nestec Sa Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
MX2015009392A (es) * 2013-01-21 2015-10-15 Abbvie Inc Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.
JP6565121B2 (ja) 2013-03-21 2019-08-28 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 代謝障害を治療する方法
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
WO2015110989A1 (en) * 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
WO2015155766A1 (en) * 2014-04-10 2015-10-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
US10473669B2 (en) * 2014-05-09 2019-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2015175926A1 (en) * 2014-05-15 2015-11-19 Children's Medical Center Corporation Systems and methods for identifying neurobiological biomarkers using eeg
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
WO2016088068A1 (en) 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
MX2017007232A (es) 2014-12-05 2017-10-16 Nestec Sa Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.
US20180224464A1 (en) * 2015-06-09 2018-08-09 Osaka University Method of predicting and determining therapeutic effect on rheumatoid arthritis due to biological formulation
CN108351862B (zh) 2015-08-11 2023-08-22 科格诺亚公司 利用人工智能和用户输入来确定发育进展的方法和装置
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
EP3448397A4 (en) * 2016-04-26 2020-01-08 Qu Biologics Inc. THERAPEUTIC INITIATION OF A BORN IMMUNE RESPONSE IN A TARGET TISSUE
EP3458466B1 (en) 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
US20180144820A1 (en) 2016-10-24 2018-05-24 Habit, Llc System and method for implementing meal selection based on vitals, genotype and phenotype
WO2018085937A1 (en) * 2016-11-14 2018-05-17 Qu Biologics Inc. Managing site specific ibd immunotherapies
CA3053245A1 (en) * 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
EP3612843A1 (en) 2017-05-31 2020-02-26 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in crohn's disease patients
KR20200069333A (ko) 2017-10-10 2020-06-16 프로메테우스 바이오사이언시즈, 인크. 베돌리주맙 치료를 모니터링하는 방법
US11270800B1 (en) * 2017-11-09 2022-03-08 Aptima, Inc. Specialized health care system for selecting treatment paths
KR102424222B1 (ko) * 2017-11-13 2022-07-21 더 멀티플 마이얼로머 리서치 파운데이션, 인크. 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
CA3134521A1 (en) 2019-03-22 2020-10-01 Cognoa, Inc. Personalized digital therapy methods and devices
CN109998488B (zh) * 2019-04-13 2022-08-02 中国医学科学院北京协和医院 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
WO2020264426A1 (en) 2019-06-27 2020-12-30 Scipher Medicine Corporation Developing classifiers for stratifying patients
US20210139857A1 (en) * 2019-11-13 2021-05-13 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
WO2023055955A1 (en) * 2021-09-30 2023-04-06 Prometheus Laboratories Inc. Patient centric precision model for anti-tnf therapy
EP4415607A1 (en) * 2021-10-15 2024-08-21 The Trustees Of Indiana University Methods for detecting fracture-related infection (fri)
CN114859060A (zh) * 2022-05-06 2022-08-05 广州市胸科医院 一种细胞因子组及其应用
US11887720B1 (en) * 2023-01-23 2024-01-30 Kpn Innovations, Llc Apparatus and method for using a feedback loop to optimize meals

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333167T2 (de) 1992-10-29 2004-06-09 Bayer Corp. Diagnostischer test spezifisch für die latente matrix metalloproteinase no. 9
ATE193601T1 (de) 1993-03-10 2000-06-15 Cedars Sinai Medical Center Verfahren zum selektiven nachweis von perinuklearen anti-neutrophilen cytoplasmischen antikörpern bei ulzerativen kolitis oder primärer sclerotischer cholangitis
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
US20020025553A1 (en) 1996-01-04 2002-02-28 Ying-Fei Wei Transforming growth factor alpha HIII
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US6319899B1 (en) 1997-09-17 2001-11-20 The Nemours Foundation Method and composition for the treatment of inflammatory bowel disease
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
RU2141332C1 (ru) 1998-06-24 1999-11-20 Научно-исследовательский институт фармакологии Томского научного центра РАМН Противоязвенное средство и способ его получения
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
FR2806739B1 (fr) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
JP2004528814A (ja) 2000-10-13 2004-09-24 チルドレンズ メディカル センター コーポレーション 組織再構築関連状態についての非侵襲性酵素スクリーニング
ES2400552T3 (es) 2000-10-30 2013-04-10 The Regents Of The University Of Michigan Ácidos nucleicos y proteínas NOD2
US6858391B2 (en) 2000-10-30 2005-02-22 Regents Of The University Of Michigan Nod2 nucleic acids and proteins
EP1340078B1 (en) 2000-11-14 2009-05-27 Techlab, Inc. Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrin as a marker
US20050154536A1 (en) 2001-08-30 2005-07-14 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Two-part drug discovery system
WO2003021257A1 (en) 2001-08-30 2003-03-13 The University Of Pittsburgh Of The Commonwealth System Of Higher Education Of Pennsylvania Algorithm for estimating the outcome of inflammation following injury or infection
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
EP1554580B1 (en) 2002-10-25 2008-05-14 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
EP1667669A2 (en) 2003-05-30 2006-06-14 Molecular Staging, Inc. Inflammatory bowel diseases
BRPI0411784A (pt) 2003-06-23 2006-08-08 Genetics Inst Llc anticorpos contra interleucina -22 e usos para os mesmos
US7439019B2 (en) 2003-11-03 2008-10-21 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction
EA012872B1 (ru) 2004-01-09 2009-12-30 Пфайзер Инк. АНТИТЕЛА ПРОТИВ MAdCAM
FI119572B (fi) 2004-03-05 2008-12-31 Biohit Oyj Menetelmä vatsan limakalvon tilan ennustamiseksi
US20060019410A1 (en) 2004-07-21 2006-01-26 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
WO2006027321A1 (en) 2004-09-09 2006-03-16 Universite De Liege Identification and use of biomarkers for the diagnosis and the prognosis of inflammatory diseases.
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
CN101291693B (zh) 2005-10-26 2012-10-03 诺瓦提斯公司 IL-1β化合物的新用途
US20080031882A1 (en) 2006-06-19 2008-02-07 Liang Spencer C Methods of modulating IL-22 and IL-17
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
NZ575827A (en) 2006-09-21 2012-02-24 Prometheus Lab Inc Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
US8165819B2 (en) 2006-10-10 2012-04-24 The University of Pittsburgh—Of the Commonwealth System of Higher Education Modeling wound healing
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US20100255513A1 (en) 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
GB2447865A (en) 2007-03-30 2008-10-01 Ethicon Inc Diagnostic markers of wound infection
EP2160475A4 (en) 2007-05-22 2011-02-09 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR EVALUATING AND TREATING CROHN'S DISEASE AND ASSOCIATED DISORDERS
ES2526211T3 (es) 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
EP2274699A4 (en) 2008-03-26 2011-04-27 Theranos Inc METHOD AND SYSTEMS FOR EVALUATING CLINICAL RESULTS
EP2307563B1 (en) * 2008-03-28 2014-08-06 Katholieke Universiteit Leuven KU Leuven Research & Development Mucosal gene signatures
US20110160085A1 (en) * 2008-08-25 2011-06-30 Katherine Li Biomarkers for anti-tnf treatment in ulcreative colitis and related disorders
AU2009285644B2 (en) * 2008-08-29 2015-08-20 Janssen Biotech, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
ES2553415T3 (es) 2009-04-14 2015-12-09 Nestec S.A. Método de pronóstico de la enfermedad intestinal inflamatoria
WO2010127057A2 (en) 2009-05-01 2010-11-04 Meso Scale Technologies, Llc. Biomarkers of therapeutic responsiveness
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
AU2010266028B2 (en) 2009-06-25 2015-04-30 Société des Produits Nestlé S.A. Methods for diagnosing irritable bowel syndrome
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
JP5675829B2 (ja) * 2009-10-15 2015-02-25 クレッシェンド バイオサイエンス インコーポレイテッド 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法
EP2491385B1 (en) 2009-10-20 2017-05-10 DiaTech Holdings, Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
NZ599456A (en) 2009-10-26 2014-06-27 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
BR112012012513A2 (pt) 2009-11-25 2017-01-10 Prometheus Lab Inc método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo
JP2013520208A (ja) 2010-02-24 2013-06-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 自己免疫疾患の診断、予後判定、及び処置法
JP2013528389A (ja) 2010-06-04 2013-07-11 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善させる方法
EP2606353A4 (en) 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASE
MX2013007429A (es) 2010-12-23 2014-01-31 Nestec Sa Seleccion de farmacos para terapia de cancer maligno usando disposiciones a base de anticuerpos.
CA2828052A1 (en) 2011-03-02 2012-09-07 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
MX362132B (es) 2011-05-10 2019-01-07 Nestec Sa Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
CA2852954A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
EP3217179B9 (en) 2012-10-05 2020-06-10 Prometheus Biosciences, Inc. Methods for predicting and monitoring mucosal healing
US20140113306A1 (en) 2012-10-17 2014-04-24 Rutgers, The State University Of New Jersey Diagnostic and screening methods for inflammation
CA2896764C (en) 2013-01-03 2023-10-31 Meso Scale Technologies, Llc Assay panels
US20140236166A1 (en) 2013-02-15 2014-08-21 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for distinguishing benign, pre-malignant, and malignant pancreatic cysts
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
CA2973433A1 (en) 2015-01-23 2016-07-28 Nestec S.A. Nutritional composition useful in the treatment of ibd patients
CN113209289A (zh) 2015-02-26 2021-08-06 豪夫迈·罗氏有限公司 治疗Crohn病的整联蛋白β7拮抗剂和方法
EP3612843A1 (en) 2017-05-31 2020-02-26 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in crohn's disease patients
WO2020117795A1 (en) 2018-12-04 2020-06-11 Prometheus Biosciences, Inc. Assessment and monitoring of mucosal healing in children and adults with crohn's disease

Also Published As

Publication number Publication date
BR112013028808A2 (pt) 2016-09-06
JP2018072349A (ja) 2018-05-10
IL229120B (en) 2018-05-31
CN103649336A (zh) 2014-03-19
AU2012253422B2 (en) 2015-08-13
US20220096629A1 (en) 2022-03-31
NZ617009A (en) 2015-09-25
US20140141983A1 (en) 2014-05-22
JP2014517279A (ja) 2014-07-17
JP2020098213A (ja) 2020-06-25
SG194710A1 (en) 2013-12-30
CA2839792A1 (en) 2012-11-15
MX2013013096A (es) 2014-07-14
KR20140032424A (ko) 2014-03-14
AU2012253422A1 (en) 2013-05-02
RU2013154566A (ru) 2015-06-20
US11160863B2 (en) 2021-11-02
IL229120A0 (en) 2013-12-31
EP2707504A1 (en) 2014-03-19
CN110544517A (zh) 2019-12-06
NZ711144A (en) 2017-01-27
ZA201309258B (en) 2016-08-31
US20190060449A1 (en) 2019-02-28
WO2012154987A1 (en) 2012-11-15
US10086072B2 (en) 2018-10-02
MX2018008324A (es) 2021-11-16

Similar Documents

Publication Publication Date Title
MX2018008324A (es) Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
MX358517B (es) Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
BR112015025944A2 (pt) tratamento e monitoração do prognóstico de distúrbios de proliferação usando inibidores do caminho do hedgehog
CL2015002807A1 (es) Terapia de combinación
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
IN2015KN00550A (es)
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
AR080643A1 (es) Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
IN2012DN03817A (es)
MX341896B (es) Biomarcadores para el tratamiento de psoriasis.
EA201590773A1 (ru) Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа)
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
BR112013025782A2 (pt) métodos de monitoramento e análise de diagnósticos de perfis de atividade metabólica e usos terapêuticos dos mesmos
TN2015000019A1 (en) Prediction of treatment response to jak/stat inhibitor
MX2017009427A (es) Inhibidores de mir-92 y usos de los mismos.
MX2014005749A (es) Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp).
MX2016008045A (es) Biomarcadores de lipogenesis de novo y metodos de uso de los mismos.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
EP2601315A4 (en) PREDICTION AND FOLLOW-UP OF THE RESPONSE TO ANTICANCER THERAPY BASED ON THE PROFILING OF GENE EXPRESSION
NZ712300A (en) Falz for use as a target for therapies to treat cancer

Legal Events

Date Code Title Description
FG Grant or registration